<DOC>
	<DOCNO>NCT02250651</DOCNO>
	<brief_summary>This study evaluate efficacy safety bimatoprost sustained-release ( SR ) patient open-angle glaucoma ocular hypertension . The study include 12-month treatment period 8-month extended follow-up .</brief_summary>
	<brief_title>Safety Efficacy Bimatoprost Sustained-Release ( SR ) Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Diagnosis either openangle glaucoma ocular hypertension eye eye require IOPlowering treatment . Previous enrollment Allergan Study 192024041D Eye surgery ( include cataract surgery ) and/or eye laser surgery within past 6 month study eye Anticipated need laser eye surgery within first 52 week study duration History glaucoma surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>